Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Deborah M. Messemer Sells 9,136 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Deborah M. Messemer sold 9,136 shares of Allogene Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $2.18, for a total transaction of $19,916.48. Following the transaction, the director now directly owns 157,629 shares in the company, valued at $343,631.22. This represents a 5.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Allogene Therapeutics Price Performance

NASDAQ ALLO opened at $2.19 on Wednesday. Allogene Therapeutics, Inc. has a one year low of $1.99 and a one year high of $5.78. The business’s fifty day moving average is $2.58 and its 200-day moving average is $2.59. The stock has a market capitalization of $459.18 million, a price-to-earnings ratio of -1.40 and a beta of 0.83.

Institutional Investors Weigh In On Allogene Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its stake in Allogene Therapeutics by 340.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock valued at $4,073,000 after acquiring an additional 1,351,055 shares during the period. Dimensional Fund Advisors LP raised its stake in Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after acquiring an additional 507,021 shares during the period. The Manufacturers Life Insurance Company raised its stake in Allogene Therapeutics by 70.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock valued at $1,119,000 after acquiring an additional 198,231 shares during the period. Primecap Management Co. CA raised its stake in Allogene Therapeutics by 4.1% in the 2nd quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock valued at $13,212,000 after acquiring an additional 221,840 shares during the period. Finally, TD Asset Management Inc raised its stake in Allogene Therapeutics by 82.7% in the 2nd quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock valued at $1,862,000 after acquiring an additional 361,904 shares during the period. 83.63% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ALLO has been the topic of a number of analyst reports. Piper Sandler cut their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.73.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).